64 related articles for article (PubMed ID: 23749892)
1. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.
Koller CM; Kim Y; Schmidt-Wolf IG
Anticancer Res; 2013 Jun; 33(6):2435-40. PubMed ID: 23749892
[TBL] [Abstract][Full Text] [Related]
2. Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
Messina CS; Weiher H; Schmidt-Wolf IG
Anticancer Res; 2017 Feb; 37(2):555-559. PubMed ID: 28179301
[TBL] [Abstract][Full Text] [Related]
3. Effect of Wnt inhibitors in pancreatic cancer.
Wall I; Schmidt-Wolf IG
Anticancer Res; 2014 Oct; 34(10):5375-80. PubMed ID: 25275031
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/beta-catenin pathway in renal cell carcinoma.
Von Schulz-Hausmann SA; Schmeel LC; Schmeel FC; Schmidt-Wolf IG
Anticancer Res; 2014 Aug; 34(8):4101-8. PubMed ID: 25075035
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
6. Targeting cancer with a bi-functional peptide: in vitro and in vivo results.
Meschenmoser K; Kim Y; Franken S; Nowak M; Feldmann G; Bendas G; Wolfgarten M; Messmer D; Schmidt-Wolf IG
In Vivo; 2013; 27(4):431-42. PubMed ID: 23812212
[TBL] [Abstract][Full Text] [Related]
7. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide.
Sioud M; Mobergslien A
Biochem Pharmacol; 2012 Nov; 84(9):1123-32. PubMed ID: 22922046
[TBL] [Abstract][Full Text] [Related]
8. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells.
Okuhashi Y; Itoh M; Nara N; Tohda S
Anticancer Res; 2011 Mar; 31(3):893-6. PubMed ID: 21498710
[TBL] [Abstract][Full Text] [Related]
11. A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.
Zennami K; Yoshikawa K; Kondo E; Nakamura K; Upsilonamada Y; De Velasco MA; Tanaka M; Uemura H; Shimazui T; Akaza H; Saga S; Ueda R; Honda N
Oncol Rep; 2011 Aug; 26(2):327-33. PubMed ID: 21567093
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
13. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Song S; Christova T; Perusini S; Alizadeh S; Bao RY; Miller BW; Hurren R; Jitkova Y; Gronda M; Isaac M; Joseph B; Subramaniam R; Aman A; Chau A; Hogge DE; Weir SJ; Kasper J; Schimmer AD; Al-awar R; Wrana JL; Attisano L
Cancer Res; 2011 Dec; 71(24):7628-39. PubMed ID: 22009536
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
17. Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries.
Su YH; Chiang LW; Jeng KC; Huang HL; Chen JT; Lin WJ; Huang CW; Yu CS
Bioorg Med Chem Lett; 2011 Mar; 21(5):1320-4. PubMed ID: 21315586
[TBL] [Abstract][Full Text] [Related]
18. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
19. Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma.
Ueno K; Hirata H; Majid S; Chen Y; Zaman MS; Tabatabai ZL; Hinoda Y; Dahiya R
Mol Carcinog; 2011 Jun; 50(6):449-57. PubMed ID: 21268126
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a proapoptotic peptide towards cancer cells.
Jäkel CE; Meschenmoser K; Kim Y; Weiher H; Schmidt-Wolf IG
In Vivo; 2012; 26(3):419-26. PubMed ID: 22523294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
